Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Tenofovir-emtricitabine-efavirenz in HIV-I-infected adults in Senegal: A 96-week pilot trial in treatment-naive patients
Journal of the International Association of Physicians in AIDS Care, Volume 8, No. 6, Year 2009
Notification
URL copied to clipboard!
Description
We report the results of a pilot open-label trial of a tenofovir (TDF)/emtricitabine (FTC)/efavirenz (EFV) combination conducted in Dakar, Senegal. Forty HIV-1-infected patients, naive of antiretroviral treatment and without active opportunistic disease, were included and followed through 96 weeks. At weeks 48 and 96, respectively, 82.5% and 85% of patients had HIV-1 RNA <400 copies/mL (72.5% and 77.5% with HIV-1 RNA <50 copies/mL). Between baseline and week 96, the mean (SD) CD4 count increased from 126 (102) to 338 (155) cells/mm 3. The mean (SD) creatinine clearance decreased from 92 (36) to 73 (19) mL/min (P =.001). Treatment adherence was at least 94% at all scheduled visits. The efficacy and tolerability of a TDF/FTC/EFV combination were high and similar to those observed in Northern countries. This drug combination can be recommended in limited-resource countries, as did the World Health Organization (WHO) and should be made readily available as a fixed-dose combination. © 2009 The Author(s).
Authors & Co-Authors
Landman, Roland
France, Paris
Hôpital Bichat-claude-bernard Ap-hp
Poupard, Marie P.
France, Paris
Hôpital Bichat-claude-bernard Ap-hp
Diallo, Mamadou Baila
Senegal, Dakar
Centre Hospitalier Universitaire Dakar
Ngom-Guèye, Ndèye Fatou
Senegal, Dakar
Centre Hospitalier Universitaire Dakar
Diakhaté, Ndella D.
Senegal, Dakar
Centre Hospitalier Universitaire Dakar
Ndiaye, Barra K.
Senegal, Dakar
Centre Hospitalier Universitaire Dakar
Touré-Kâne, Coumba
Senegal, Dakar
Université Cheikh Anta Diop de Dakar
Trylesinski, A.
France, Paris
Gilead Sciences
Diop-Ndiaye, Halimatou
Senegal, Dakar
Université Cheikh Anta Diop de Dakar
Mboup, Souleymane
France, Paris
Gilead Sciences
Koita-Fall, M. B.
Senegal, Dakar
Centre Hospitalier Universitaire Dakar
Delaporte, Éric
France, Montpellier
Ird Centre de Montpellier
Benalycherif, Aïda
France, Paris
Hôpital Bichat-claude-bernard Ap-hp
Girard, Pierre Marie
France, Paris
Hôpital Bichat-claude-bernard Ap-hp
France, Paris
Hôpital Saint-antoine
Sow, Papa Salif
Senegal, Dakar
Centre Hospitalier Universitaire Dakar
Statistics
Citations: 15
Authors: 15
Affiliations: 6
Identifiers
Doi:
10.1177/1545109709344352
ISSN:
15451097
e-ISSN:
15570886
Research Areas
Infectious Diseases
Study Locations
Senegal